Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - rabies vaccine, wistar pm/wi 38-1503-3m 3.25 [iu] (target quantity per dose) - powder for injection with diluent - 3.25 iu - active: rabies vaccine, wistar pm/wi 38-1503-3m 3.25 [iu] (target quantity per dose) excipient: albumin hydrochloric acid bme medium - mineral salts, vitamins, amino acids including l-phenylalanine maltose sodium hydroxide sodium chloride water for injection - verorab is indicated for pre-exposure prophylaxis against rabies. verorab is indicated for post-exposure prophylaxis against rabies. verorab should be used in accordance with official local recommendations.

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - eftrenonacog alfa 1000 [iu];   - powder for infusion - 1000 iu - active: eftrenonacog alfa 1000 [iu]   excipient: histidine mannitol polysorbate 20 sucrose sodium chloride water for injection - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - eftrenonacog alfa 2000 [iu];   - powder for infusion - 2000 iu - active: eftrenonacog alfa 2000 [iu]   excipient: histidine mannitol polysorbate 20 sucrose sodium chloride water for injection - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - eftrenonacog alfa 250 [iu];   - powder for infusion - 250 iu - active: eftrenonacog alfa 250 [iu]   excipient: histidine mannitol polysorbate 20 sucrose sodium chloride water for injection - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - eftrenonacog alfa 3000 [iu];   - powder for infusion - 3000 iu - active: eftrenonacog alfa 3000 [iu]   excipient: histidine mannitol polysorbate 20 sucrose sodium chloride water for injection - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - eftrenonacog alfa 500 [iu];   - powder for infusion - 500 iu - active: eftrenonacog alfa 500 [iu]   excipient: histidine mannitol polysorbate 20 sucrose sodium chloride water for injection - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - follitropin alfa 150 [iu] (11 mcg) - solution for injection - 600 iu/ml - active: follitropin alfa 150 [iu] (11 mcg) excipient: dibasic sodium phosphate dihydrate methionine monobasic sodium phosphate dihydrate phosphoric acid poloxamer sucrose water for injection - in adult men: bemfola is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - follitropin alfa 225 [iu] (16.5 mcg) - solution for injection - 600 iu/ml - active: follitropin alfa 225 [iu] (16.5 mcg) excipient: dibasic sodium phosphate dihydrate methionine monobasic sodium phosphate dihydrate phosphoric acid poloxamer sucrose water for injection - in adult men: bemfola is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - follitropin alfa 300 [iu] (22 mcg) - solution for injection - 600 iu/ml - active: follitropin alfa 300 [iu] (22 mcg) excipient: dibasic sodium phosphate dihydrate methionine monobasic sodium phosphate dihydrate phosphoric acid poloxamer sucrose water for injection - in adult men: bemfola is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - follitropin alfa 450 [iu] (33 mcg) - solution for injection - 600 iu/ml - active: follitropin alfa 450 [iu] (33 mcg) excipient: dibasic sodium phosphate dihydrate methionine monobasic sodium phosphate dihydrate phosphoric acid poloxamer sucrose water for injection - in adult men: bemfola is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.